<?xml version="1.0" encoding="UTF-8"?>
<p id="par0015">As millions of cancer patients are fighting COVID-19, investigations into the incidence and clinical management of COVID-19 in patients with cancer, including renal cell carcinoma (RCC), are ongoing with intensity. This review aims to advance the current understanding of the impact of angiotensin-converting enzyme-2 (ACE2)-mediated SARS-CoV-2 infection on kidney function and the therapeutic targeting of underlying shared mechanisms of RCC and COVID-19.</p>
